IP Library Granted Patent US 9,499,475
Granted Patent B2
US 9,499,475 · App. 14/891,014 · Granted Nov 22, 2016

Process for the preparation of arformoterol or salt thereof

Inventors: Shekhar Bhaskar Bhirud (Mumbai, IN); Suresh Mahadev Kadam (Thane, IN); Sachin Baban Gavhane (Dombivli, IN); Shailesh Shrirang Pawase (Mumbai, IN); Aniket Ashokrao Deshpande (Nashik, IN); Anil Subhash Bhujbal (Dombivli, IN)
Assignee: Glenmark Pharmaceuticals Limited
C07C231/24C07C59/255C07B2200/07C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,475
App. No.
14/891,014
Granted
Nov 22, 2016
Kind
B2
Abstract

Provided is an improved process for the preparation of arformoterol L-(+)-tartrate, and more specifically provided is a novel process for the preparation of arformoterol L-(+)-tartrate via arformoterol D-(−)-tartrate.

Claims (15)

1. A process for the preparation of arformoterol L-(+)-tartrate, a compound of Formula Ia,

wherein the level of compounds of formula A or B, is less than 0.15% w/w relative to the amount of arformoterol L-(+)-tartrate as determined by HPLC,

composing: a) reacting crude arformoterol, a compound of Formula I

with D-(+)-tartaric acid to form arformoterol D-(−)-tartrate, a compound of formula II; and

b) reacting the arformoterol D-(−)-tartrate, the compound of formula II, with a base and L-(+)-tartaric acid, to form arformoterol L-(+)-tartrate, a compound of Formula Ia.

2. The process of claim 1 , wherein arformoterol D-(−)-tartrate, a compound of formula II, is subjected to purification.

3. The process of claim 2 , wherein arformoterol D-(−)-tartrate, a compound of formula II, is subjected to purification by crystallization in a solvent system.

4. The process of claim 3 , wherein the solvent system comprises ether and water.

5. The process of claim 1 , wherein arformoterol D-(−)-tartrate, a compound of formula II has a chemical purity of at least 95% as determined by HPLC.

6. The process of claim 1 , wherein in step b) the arformoterol D-(−)-tartrate, the compound of formula II, is reacted with a base to obtain arformoterol, followed by reacting the arformoterol with L-(+)-tartaric acid in a mixture of toluene and isopropanol to form arformoterol L-(+)-tartrate.

7. The process of claim 6 , wherein the isopropanol and toluene are used in the ratio of 8:2 v/v.

8. The process of claim 6 , wherein an aqueous solution of L-(+)-tartaric acid is used.

9. The process of claim 8 , wherein the aqueous solution of L-(+)-tartaric acid is used in a proportion such that isopropanol:toluene:water is in the ratio of 8:2:1 v/v, for 1 part by weight of arformoterol D-(−)-tartrate.

10. The process of claim 9 , wherein the arformoterol L-(+)-tartrate, to compound of Formula Ia, is isolated in crystalline polymorphic Form B.

11. The process of claim 1 , wherein arformoterol D-(−)-tartrate, the compound of formula II, is thereafter convened to arformoterol L-(+)-tartrate, a compound of Formula Ia.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2015
From: BHIRUD, SHEKHAR BHASKAR; KADAM, SURESH MAHADEV; GAVHANE, SACHIN BABAN; PAWASE, SHAILESH SHRIRANG; DESHPANDE, ANIKET ASHOKRAO; BHUJBAL, ANIL SUBHASH
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 037140/0901 →
MERGER Recorded Nov 25, 2015
From: GLENMARK GENERICS LIMITED
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 037159/0504 →
Priority Claims (1)
IN 1762/MUM/2013 · May 17, 2013 · national
Continuity (1)
Related Publication 20160083334A1 · Mar 24, 2016